Abound.Sqm: a Phase 3 Randomized Study of Maintenance Nab-Paclitaxel (Nab-P) After Induction Therapy with Nab-P Plus Carboplatin (C) in Patients (Pts) with Squamous Cell (Scc) Non-Small Cell Lung Cancer (Nsclc)David R. Spigel, Craig H. Reynolds, Teng Jin Ong et al.|Annals of Oncology|2014Cited by 2
nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim safety results from the phase 3 ABOUND.sqm studyE. Kim, Nataliya Trunova, Davey B. Daniel et al.|Annals of Oncology|2016Cited by 0
P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by CycleE. Kim, Corey J. Langer, J. Weiß et al.|Journal of Thoracic Oncology|2017Cited by 0